Tivicay

Chemical Namedolutegravir
Dosage FormTablet (oral; 10 mg, 25 mg, 50 mg); PD Tablet for suspension (oral; 5 mg)
Drug ClassInhibitors
SystemBlood
CompanyViiV Healthcare
Approval Year2013

Indication

  • Tivicay and Tivicay PD are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least 4 weeks and weighing at least 3 kg.
  • Tivicay is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.
Last updated on 6/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivicay (dolutegravir) Prescribing Information.2022ViiV Healthcare, Research Triangle Park, NC
Document TitleYearSource
Assessment report: Tivicay.2020EMA